Several brokerages have updated their recommendations and price targets on shares of Altimmune (NASDAQ: ALT) in the last few weeks:
- 11/14/2026 – Altimmune was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 11/13/2026 – Altimmune was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 11/13/2026 – Altimmune had its “market outperform” rating reaffirmed by Citigroup.
- 11/13/2026 – Altimmune had its “buy” rating reaffirmed by B. Riley Financial.
- 9/23/2026 – Altimmune had its “outperform” rating reaffirmed by Evercore.
- 9/21/2026 – Altimmune had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Altimmune Trading Down 1.9%
Shares of NASDAQ ALT opened at $1.53 on Wednesday. The stock has a market cap of $297.72 million, a price-to-earnings ratio of -2.12 and a beta of 0.16. The business has a 50 day simple moving average of $2.51 and a 200 day simple moving average of $3.11. Altimmune, Inc. has a 52 week low of $1.50 and a 52 week high of $6.44. The company has a debt-to-equity ratio of 0.08, a quick ratio of 23.93 and a current ratio of 23.93.
Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). On average, research analysts predict that Altimmune, Inc. will post -0.60 earnings per share for the current fiscal year.
Insider Buying and Selling
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Read More
- Five stocks we like better than Altimmune
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Altimmune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune Inc and related companies with MarketBeat.com's FREE daily email newsletter.
